

# Richard Van der Jagt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/337835/publications.pdf>

Version: 2024-02-01

9  
papers

280  
citations

1684188

5  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

601  
citing authors

#	ARTICLE	IF	CITATIONS
1	First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 984-991.	1.6	183
2	Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. <i>Haematologica</i> , 2016, 101, 363-370.	3.5	33
3	Cognitive function and its relationship to other psychosocial factors in lymphoma survivors. <i>Supportive Care in Cancer</i> , 2017, 25, 905-913.	2.2	21
4	First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7500-7500.	1.6	18
5	Coexisting Mantle Cell Lymphoma and Prostate Adenocarcinoma. <i>Case Reports in Medicine</i> , 2014, 2014, 1-4.	0.7	10
6	Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes. <i>Expert Review of Hematology</i> , 2013, 6, 525-537.	2.2	5
7	Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. <i>Leukemia and Lymphoma</i> , 2006, 47, 697-706.	1.3	4
8	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 766-774.	0.4	4
9	Dyserythropoiesis due to reactive hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2016, 128, 2190-2190.	1.4	2